

Imaging methods in diagnosis of bladder cancers

Mohammed Adel Mohammed Shami, Mohammed Abdulrazag Althubaiti, Abdulaziz Musaed Al thaqafi, Ahmed Mohammed Ali Althobaiti

Abstract:

Urinary bladder cancer is a heterogeneous disease with a variety of pathologic features, cytogenetic characteristics, and natural histories. This review discusses improvements in staging, with particular focus on the most recent advances in imaging techniques for urothelial carcinoma of the bladder. Narrative review search was performed in July 2018 using the PubMed and Embase databases for articles discussing the imaging methods in detection of bladder cancer.

Early discovery of bladder cancer is essential, because up to 47% of bladder cancer-- relevant fatalities may have been avoided. Conventional CT and MR imaging are only moderately exact in the diagnosis and local staging of bladder cancer; cystoscopy and pathologic staging stay the standards of reference. Whole-body CT is the primary imaging strategy for spotting metastases in affected patients, especially those with muscle-invasive condition. The function of more recent MR imaging sequences in the diagnosis and local staging of bladder cancer proceeds to evolve. Breakthroughs in MR imaging technology have made multiparametric MR imaging possible for the regional staging of bladder cancer to enhance treatment. Contrast improved ultrasound boosts uniqueness and level of sensitivity of bladder tumor detection and might function as a follow-up assessment for ambiguous ultrasound outcomes.

Introduction:

Bladder cancer is the most frequent kind of tumor of the urinary tract and is most prevalent in the fifth to seventh decades of life [1]. Clinical managing of urinary bladder cancer is identified mostly on the basis of differentiating superficial tumors (stage T1 or lower) from invasive ones (phase T2 or higher), because the treatment choices differ significantly. Superficial tumors are managed with transurethral resection with or without adjuvant intravesical chemotherapy or photodynamic therapy [2], whereas invasive tumors are treated with radical cystectomy, radiation therapy, chemotherapy, or a mix of these [3]. Therefore, preoperative imaging could be crucial to medical diagnosis if maybe made use of to differentiate exactly in between both groups of bladder cancer. Magnetic resonance (MR) imaging is significantly utilized in the detection of bladder cancer [4]. It can also aid enhance the determination of tumor extent. Writers of lots of research studies have investigated the accuracy of MR imaging in regional staging [5], [6].

Urinary bladder cancer is a heterogeneous disease with a variety of pathologic features, cytogenetic characteristics, and natural histories. This review discusses improvements in staging ,with particular focus on the most recent advances in imaging techniques for urothelial carcinoma of the bladder.

Methodology:

Narrative review search was performed in July 2018 using the PubMed and Embase databases for articles discussing the imaging methods in detection of bladder cancer. We limited to articles published in English language with human subjects. Furthermore, references list of each found articles were reviewed for more relevant studies to support our review article.

Discussion:

- **Pathologic Features**

Regarding 90% of bladder tumors are urothelial in beginning (ie, transitional cell carcinomas). Squamous cell cancers make up 6%-8% of all bladder cancers cells [7], [8]. Adenocarcinomas are rare and usually stand for urachal cancer. Approximately 25% of urothelial cancers cells have a blended histology that consists of small cell neuroendocrine, micropapillary (resembling serous papillary cancer of the ovary), sarcomatoid, and plasmacytoid elements. These variants have considerably worse prognoses compared to do the pure urothelial cancers cells. One of the most usual etiologic factors for urothelial tumors are smoking and job-related direct exposure to chemical health hazards such as aniline dyes [9],[10]. Cigarette cigarette smoking is believed to be the causative consider 50%-60% of men and one-third of females who develop bladder cancer [11],[12]. The relative threat of existing smokers for fatality from bladder cancer is 3.3 in males and 2.2 in women. Iatrogenic threat aspects for urothelial tumors are restorative irradiation of

surrounding body organs and using alkylating representatives. Although it is rare, there is a genetic tendency to the development of urothelial tumors in some families [13],[14].Threat elements for squamous cell cancer consist of long-lasting catheterization, nonfunctioning bladder, urinary system calculi, and chronic infection by Schistosoma hematobium.

Urothelial tumors are classified as either invading muscle (nonpapillary) or not invading muscle (superficial or papillary). About 80%-85% of urothelial tumors are non-muscle invasive. These are low-grade sores, could be multifocal, and arise from a hyperplastic epithelium. They usually have a great prospects and rarely develop into an invasive cancer, although urothelial reoccurrence rates have to do with 50% [15], [16]. Approximately 20%-25% of bladder cancers are muscle invasive, emerge from serious dysplasia or carcinoma sitting, and have a higher histologic grade [17].Non-muscle-invasive urothelial tumors have a greater rate of reoccurrence compared to do the muscle-invasive selection. If left without treatment, they are a forerunner of muscleinvasive tumors. Almost all situations of squamous carcinoma and adenocarcinoma of the bladder are invasive at the time of diagnosis. These two kinds of bladder cancer could bring a worse prospects than do urothelial tumors, despite having hostile surgical therapy and chemotherapy.

- **Genetic Characteristics**

Non-muscle-invasive and muscle-invasive tumors behave in a different way because they harbor distinctive hereditary defects and develop along 2 separate pathways (Fig 1). Non-muscle-invasive tumors are identified by activating mutations in the HRAS gene and fibroblast growth element. These genes contribute in regulating the RTK (receptor tyrosine kinase)/ RAS signaling pathway. Activation of the RTK/RAS pathway results in the growth of hatred. Patients with nonmuscle-invasive tumors might gain from RTK/ RAS pathway inhibition. Muscle-invasive

tumors are characterized by structural and functional flaws in the p53 and retinoblastoma tumor suppressor paths. Both of these proteins play vital duties in cell cycle control [18], [19]. These high-grade tumor versions have a tendency to technique regardless of extreme surgery, yet influenced patients might potentially benefit from substitute treatments that recover the functions of p53 and retinoblastoma. On the basis of the molecular pathogenesis of bladder cancer, a number of U.S. Food and Drug Administration- authorized biomarkers are offered for forecasting disease reappearance and survival after extreme cystectomy [20]. To date, however, none of the accepted biomarker assays remove the demand for analysis or surveillance cystoscopy [21].




Figure 1. Chart illustrates the molecular biology of muscle-invasive and non-muscle-invasive papillary tumors [18-21].

- **Symptoms**

The most typical presenting symptom of bladder cancer is painless macroscopic haematuria. The prevalence of bladder cancer in patients with macroscopic haematuria is between 12 and 20% [22]. Various other presenting signs consist of unexplained urinary frequency, urgency and

dysuria. Pelvic discomfort and symptoms because of urinary tract obstruction are located in advanced tumors. Bladder cancer is organized utilizing the TNM (tumornode-metastasis) staging system (Table1) [23].In this system, T phase is based upon the level of invasion of the bladder wall surface (Fig 2).

Table 2. TNM Guidelines for the Staging of Urinary Bladder Cancer[23].

Descriptor	Definition
Tumor	
Tx	Primary tumor cannot be evaluated
T0	No primary tumor
Ta	Noninvasive papillary carcinoma
Tis	Carcinoma in situ
T1	Tumor invades connective tissue under the epithelium (surface layer)
T2	Tumor invades muscle
T2a	Superficial muscle affected (inner half)
T2b	Deep muscle affected (outer half)
T3	Tumor invades perivesical fat
T3a	Tumor is detected microscopically
T3b	Extravesical tumor is visible macroscopically
T4	Tumor invades the prostate gland, uterus, vagina, pelvic wall, or abdominal wall
Node	
Nx	Regional lymph nodes cannot be evaluated
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node<2 cm in size
N2	Metastasis in a single lymph node> 2 cm but< 5 cm in size , or multiple lymph nodes< 5 cm in size
N3	Metastasis in a lymph node>5 cm in size
Metastasis	
Mx	Distant metastasis cannot be evaluated
M0	No distant metastasis
M1	Distant metastasis




Figure 2. Drawing illustrates the layers of the bladder wall and tumor staging based on depth of invasion. (See Table for T stage definitions)[23].

- **Diagnosis**

Cystoscopy

Cystoscopy continues to be the gold requirement for visualization and medical diagnosis of bladder tumors. Due to the fact that some malignant sores may not be obvious on white light cystoscopy, several teams have checked out methods to enable even more accurate identification of suspicious areas. Methods such as optical comprehensibility tomography and hexaminolevulinate-induced fluorescent light-guided cystoscopy have shown assurance but have substantial constraints [25], [24]. This section will certainly focus on renovations in the diagnostic capacities of ultrasound, CT, and MRI.

Ultrasound

Cystoscopy is an invasive method that may be uncomfortable for patients and can result in infection or, rarely, stricture. Noninvasive diagnostic methods have been studied in the discovery of bladder cancer however have shown deficiencies in the ability to recognize small tumors. Ultrasound has a minimal duty in the medical diagnosis of bladder cancer; nonetheless, contrast-enhanced methods have been employed to enhance the accuracy of ultrasound. Nicolau et al. [26] executed contrast-enhanced ultrasound in 43 patients before transurethral resection of known bladder tumors and determined its accuracy in comparison to common ultrasound. Contrast-enhanced ultrasound offered a greater precision for tumor detection compared with common ultrasound (88.37% vs. 72.09%) yet did not carry out well in finding tumors < 5 mm in size (sensitivity 20%, NPV 28.57%). In this research, the benefit of contrast-enhanced ultrasound remained in making clear unpredictable outcomes, as the method accurately determined 7 of 8 lesions regarded equivocal on common ultrasound.

Computed Tomography urography

Multidetector row computed tomography (CT) urography is the recommended imaging technique for the medical diagnosis and staging of upper urinary tract and BCa(bladder cancer) [27].CT urography has high diagnostic accuracy for urothelial cancers contrasted with intravenous urography (IVU) [28-31], yet has the disadvantage of higher radiation exposure. 64-CT modern technology with isotropic submillimeter spatial resolution supplies identical diagnostic capability to computed radiography. The coronal spatial resolution of a 64-CT system is reported to be similar to that of conventional excretory urography utilizing computed radiography [32].A 64-CT scanner is able to find the smallest filling defects (0.25 mm) in a phantom model, which resemble the smallest filling defects that have been commonly identified by purgative urography,

consisting of pyeloureteritis cystica and urothelial cancer [32]. The reliable dosage for CT urography could be substantially lowered (from 66.3 to 27.2 mSv) by restricting the CT exam coverage (summed over all the scan stages) and reliable selection of procurement specifications (detector configuration, pitch, tube current-- time item). The usage of a low-dose unenhanced collection could additionally decrease the minimum dosage to 20.1 mSv. Such dose-reducing procedures do not jeopardize photo quality, as by utilizing the lowest effective-dose CT urography procedure, loading defects of 0.25 mm may be accurately identified making use of 64-CT modern technology, equal to the efficiency making use of computed radiography.

This implies an extensive evaluation of haematuria and for suspected urothelial cancer could be performed at an effective dosage of approximately 20.1 mSv, which is 8.2 mSv greater than that of a conventional excretory urography examination (11.9 mSv) including 5 KUBs (kidneys, ureters and bladder) (anteroposterior), one KUB (susceptible), 3 kidney radiographs and 8 kidney tomograms [32]. Greater diagnostic abilities of CT compared to traditional excretory urography are well documented for the discovery of urinary system calculi [33],[34] renal masses [35], urothelial lesions [28],[31] and extraurinary findings [36] This enhancement in diagnostic capacities surpasses the use of enhanced radiation dose for CT urography. Additionally, when a conventional excretory urography assessment is undetermined or additional imaging is deemed essential, the total dosage of the excretory urography evaluation and a follow-up CT assessment ($20.1 + 11.9 = 32.0$ mSv) is 60% greater than the dose from CT urography alone. So, when a full urologic analysis is needed, CT urography provides a decline in total radiation dosage, a decrease in total comparison medium dose and a reduced variety of visits for the patient relative to a traditional excretory urography examination adhered to by a urologic CT assessment [32]. More enhancements in radiation dosage optimization strategies and consensus referrals for

tailoring of CT urography to the ideal sign [27],[37] will continuously expand the growing body of scientific proof that sustains the adoption of CT urography as a substitute for excretory urography.

Along with detecting urothelial tumors of the upper tracts [38],CT urography can additionally be made use of to detect bladder tumours. Advancements in CT technology and optimized imaging procedures have boosted the visualization of the bladder and the capability to detect bladder tumors. Turney et al. [39] reported the sensitivity of CT urography for detecting BCa as 93% and the specificity as 99%. Usage of CT urography as the first-line imaging test simplifies examinations for haematuria by offering a single option to the combination of ultrasonography and IVU. The sensitivity of CT urography is not high enough for CT urography to be made use of as a solitary test for identifying BCa, but CT urography demonstrates adequate specificity for BCa that patients that are CT urography positive for BCa could go straight to stiff cystoscopy, biopsy and/or resection. If CT urography is used as a firstline imaging investigation for investigating macroscopic haematuria in risky patient groups, then approximately 20% of flexible cystoscopies may be prevented, and patients can continue directly to transurethral biopsy and resection. Further renovation in the diagnostic sensitivity of CT urography might be attainable in the future by combining the CT with a urine-based tumour marker such as nuclear matrix protein (NMP)-22.

Diagnosis: intravenous urography

IVU is made use of mainly to spot filling problems in the calices, kidney pelvis and ureters and hydronephrosis, which might show the existence of a ureteral tumor. IVU might likewise detect huge tumors, which might be viewed as filling defects in the bladder. The have to carry out routine IVU once a bladder tumor has been identified is currently doubted due to the fact that of

the low incidence of considerable findings acquired with this approach. The incidence of upper tract urothelial carcinoma (UTUC) is reduced (1.8%), but this boosts to 7.5% in tumours situated in the trigone [40].

Magnetic resonance

MRI has the advantages of intrinsic high soft tissue contrast and straight multiplanar imaging capabilities. On T1-weighted pictures, the bladder tumor usually has a low-to-intermediate signal intensity much like that of the bladder wall. On T2 heavy images, the tumor has the tendency to be a lot more conspicuous, as it contrasts with adjacent frameworks (i.e., its signal intensity is intermediate between that of the darker bladder wall muscular tissue and the better high-signal-intensity pee). Using diffusion-weighted imaging (DWI) in the staging of bladder cancer is a reasonably brand-new phenomenon. DWI is an MRI technique that generates in-vivo pictures of biological tissues weighted with the regional microstructural attributes of water diffusion. Malignant tissues have been shown to have more limited diffusion generally when compared with regular tissue. El-Assmy et al. [6] prospectively contrasted DWI with T2-weighted MRI for discovery and staging of bladder tumors. One hundred and six patients had actually T2MRI adhered to by DWI, and the results were correlated with last pathological results. DWI appropriately staged the bladder tumor in 78.3% of situations, whereas T2MRI just organized 39.6% correctly. DWI was a lot more exact compared to T2MRI in both organconfined disease (69.7% vs. 15.1%) and > pT2 disease (92.5% vs. 80.1%). DWI showed great sensitivity (98.1%) and PPV (100%) when compared to cystoscopy, with missed out on lesions being 4 mm or less. Likewise, Takeuchi et al. [41] reported the value of DWI in anticipating the stage of bladder tumors contrasted with T2MRI and T2MRI with comparison enhancement. DWI enhanced the total accuracy, specificity and ROC curves for figuring out phase \leq T1 vs. phase \geq T2. The

authors also recommended that establishing the apparent diffusion coefficient could assist in determining high-grade tumors also.

Making use of MRI in determining nodal illness has also been an area of energetic examination. Saokar et al. [42] compared searchings for of nodal participation in patients with bladder or prostate cancer. More nodes were found on MRI compared to on CT, and MRI was substantially better compared to CT in detecting nodes 1-5 mm in dimension. Various strategies have been used to more enhance the capability of MRI to detect nodal involvement. Thoeny and associates [43] integrated contrast-enhanced MRI with ultrasmall superparamagnetic bits of iron-oxide (USPIO) and DWI in 21 patients with bladder and prostate cancer whose pelvic lymph nodes were deemed typical on preoperative 3-T MRI. Last pathology exposed 26 metastatic lymph nodes, 24 of which were appropriately identified with the combination of USPIO enhanced MRI and DWI. Both remaining metastatic nodes not seen were micrometastases of 1 mm and 0.7 mm. Bellin and Roy [44] summarized the outcomes of researches of MR lymphangiography utilizing USPIO, showing a fad toward increased level of sensitivity in the discovery of metastatic lymph nodes not only in bladder cancer, however likewise in prostate and testicular cancers.

Conclusion:

Early discovery of bladder cancer is essential, because up to 47% of bladder cancer-- relevant fatalities may have been avoided. Conventional CT and MR imaging are only moderately exact in the diagnosis and local staging of bladder cancer; cystoscopy and pathologic staging stay the standards of reference. Whole-body CT is the primary imaging strategy for spotting metastases in affected patients, especially those with muscle-invasive condition. The function of more recent MR imaging sequences in the diagnosis and local staging of bladder cancer proceeds to evolve. Breakthroughs in MR imaging technology have made multiparametric MR imaging possible for the regional staging of bladder cancer to enhance treatment. Contrast improved ultrasound boosts uniqueness and level of sensitivity of bladder tumor detection and might function as a follow-up assessment for ambiguous ultrasound outcomes. DW-MRI and 64-slice multidetector CT provide excellent info concerning bladder cancer tumor and nodal phase. The CT urogram is the gold common imaging study for the workup of hematuria. More advances in three-dimensional innovation and higher resolution machines will likely boost the accuracy of these modalities.

Reference:

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58(2):71–96. <https://doi.org/10.3322/CA.2007.0010>
2. Josephson D, Pasin E, Stein JP. Superficial bladder cancer: part 2. Management. *Expert Rev Anticancer Ther* 2007;7(4):567–581.
3. Sherif A, Jonsson MN, Wiklund NP. Treatment of muscle-invasive bladder cancer. *Expert Rev Anticancer Ther* 2007;7(9):1279–1283.
4. Fisher MR, Hricak H, Tanagho EA. Urinary bladder MR imaging. Part II. Neoplasm. *Radiology* 1985;157(2):471–477.
5. Daneshmand S, Ahmadi H, Huynh LN, Dobos N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. *Urology* 2012;80(6): 1313–1318.

6. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. *Eur Radiol* 2009;19(7):1575–1581.
7. Skinner DG, Lieskovsky G, eds. *Diagnosis and management of genitourinary cancer*. Philadelphia, Pa: Saunders, 1988.
8. Murphy WM, Grignon DJ, Perlman EJ. *Tumors of the kidney, bladder, and related urinary structures*. AFIP Atlas of Tumor Pathology, ser 4. Washington, DC: American Registry of Pathology, 2004.
9. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. *Urology* 2005;66(6 suppl 1):4–34.
10. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. *World J Urol* 2007;25(3):285–295.
11. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. *Cancer* 2000;89(3):630–639.
12. Steiner H, Bergmeister M, Verdorfer I, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. *BJU Int* 2008;102(3): 291–296.
13. Aben KK, Witjes JA, Schoenberg MP, Hulsbergenvan de Kaa C, Verbeek AL, Kiemeny LA. Familial aggregation of urothelial cell carcinoma. *Int J Cancer* 2002;98(2):274–278.
14. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. *Int J Cancer* 2002;99(2):260–266.
15. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. *BJU Int* 2002;89(4):369–373.
16. Sadow CA, Silverman SG, O'Leary MP, Signorovitch JE. Bladder cancer detection with CT urography in an academic medical center. *Radiology* 2008; 249(1):195–202.
17. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. *Cancer Pract* 2002;10(6):311–322.
18. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. *Cancer Res* 1998;58(6):1090–1094.
19. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. *Nat Rev Cancer* 2005;5(9):713–725.
20. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer* 2008;112(2):315–325.
21. Sexton WJ, Wiegand LR, Correa JJ, Politis C, Dickinson SI, Kang LC. Bladder cancer: a review of nonmuscle invasive disease. *Cancer Contr* 2010;17(4): 256–268.
22. Sutton JM. Evaluation of hematuria in adults. *JAMA* 1990; 263:2475– 2480.

23. Greene FL, Page DL, Fleming ID, et al, eds. Urinary bladder. In: AJCC cancer staging manual. 6th ed. New York, NY: Springer-Verlag, 2002; 335–340.
24. Karl A, Stepp H, Willmann E, et al. Optical coherence tomography for bladder cancer: ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. *Eur J Med Res* 2010; 15:131–134.
25. Schumacher MC, Holmang S, Davidsson T, et al. Transurethral resection of nonmuscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. *Eur Urol* 2010; 57:293–299.
26. Nicolau C, Bunesch L, Peri L, et al. Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. *Br J Radiol* 2010.
27. Van Der Molen AJ, Cowan NC, Mueller-Lisse UG, et al. CT urography: definition, indications and techniques. A guideline for clinical practice. *Eur Radiol* 2008; 18:4–17.
28. Cowan NC, Turney BW, Taylor NJ, et al. Multidetector computed tomography urography (MDCTU) for diagnosing upper urinary tract tumour. *BJU Int* 2007; 99:1363–1370.
29. Albani JM, Ciaschini MW, Stroom SB, et al. The role of computerized tomographic urography in the initial evaluation of hematuria. *J Urol* 2007; 177:644–648.
30. Fritz GA, Schoellnast H, Deutschmann HA, et al. Multiphase multidetector CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. *Eur Radiol* 2006; 16:1244–1252.
31. Gray Sears C, Ward JF, Sears ST, et al. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. *J Urol* 2003; 168:2457–2460.
32. Vrtiska TJ, Hartman RP, Kofler JM, et al. Spatial Resolution and Radiation Dose of a 64-MDCT Scanner Compared with Published CT Urography Protocols. *AJR Am J Roentgenol* 2009; 192:941–948.
33. Smith RC, Verga M, McCarthy S, Rosenfield AT. Diagnosis of acute flank pain: value of unenhanced helical CT. *AJR Am J Roentgenol* 1996; 166:97–101.
34. Wang JH, Shen SH, Huang SS, Hang CY. Prospective comparison of unenhanced spiral computed tomography and intravenous urography in the evaluation of acute renal colic. *J Chin Med Assoc* 2008; 71:30–36.
35. Warshauer DM, McCarthy SM, Street L, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. *Radiology* 1988; 169:363–365.
36. Liu W, Morteale KJ, Silverman SG. Incidental extraurinary findings at MDCT urography in patients with hematuria: prevalence and impact on imaging costs. *AJR Am J Roentgenol* 2005; 185:1051–1056.
37. Nolte-Ernsting C, Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. *Eur Radiol* 2006; 16:2670–2686.
38. Caoili EM, Cohan RH, Inampudi P, et al. MDCT urography of upper tract urothelial neoplasms. *AJR Am J Roentgenol* 2005; 184:1873–1881.

39. Turney BW, Willatt JMC, Nixon D, et al. Computed tomography urography for diagnosing bladder cancer. *BJU Int* 2006; 98:345–348.
40. Palou J, Rodri'guez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. *J Urol* 2005; 174:859–861.
41. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging: accuracy for diagnosing T stage and estimating histologic grade. *Radiology* 2009; 251:112–121.
42. Saokar A, Islam T, Jantsch M, et al. Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. *Clin Imaging* 2010; 34:361–366.
43. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. *Eur Urol* 2009; 55:761–769.
44. Bellin MF, Roy C. Magnetic resonance lymphography. *Curr Opin Urol* 2007; 17:65–69.

IJSER